Central Nervous System Infections Presenting to the Pediatric Intensive Care Unit

Chapter 65 Central Nervous System Infections Presenting to the Pediatric Intensive Care Unit




Life-threatening infections in the pediatric population are an all too common occurrence in the pediatric intensive care unit (PICU). These infections can come from a myriad of sources and can affect any organ system. Extremely young age, poor nutritional status, incomplete development of both innate and adaptive immune responses, and underlying disease processes all contribute to the increased risk for severe infections in the pediatric population. Infections of the central nervous system (CNS) are frequently encountered by the pediatric intensivist and often pose life-threatening challenges to the individual.


Understanding infections of the CNS entails more than a comprehension of the appropriate antimicrobial agents and laboratory tests. Recently it has become clear that CNS infections in childhood may have long-term consequences. Earlier studies focused on risk exposures of congenital infections of the CNS acquired during the fetal period. However, the human brain continues to develop well into early adulthood, and infections of the CNS during infancy and childhood may increase the risk of neuropsychiatric problems later in life. A study from South America of persons who had “epidemic meningitis” during childhood (mainly of bacterial origin) demonstrated a fivefold increase in the prevalence of psychotic disorders.1 Additionally, in a recent Swedish study of over 1 million pediatric patients, serious viral CNS infections during childhood, specifically mumps virus and cytomegalovirus (CMV), appeared to be associated with the later development of schizophrenia and other psychoses.2 The exact pathophysiology of these long-term insults is currently the focus of clinical interest. Use of new immunohistochemical staining, such as amyloid precursor protein (β-APP), along with biomarkers of axonal injury such as c-tau and α-II spectrin, may offer insight into the axonal and neuronal injury that occur both with and following CNS infections.3,4



Bacterial Meningitis


Bacterial meningitis remains a common cause of morbidity and mortality in the pediatric population. It is not infrequent for many children with bacterial meningitis to be admitted to a PICU for initial supportive care.


Many microorganisms have the ability to cause meningitis. Most microorganisms are acquired through a hematogenous route, and others through direct extension from nasal cavities, paranasal sinuses, mastoids, or the middle ear. Other microorganisms are associated with trauma or surgery with or without the placement of foreign materials. In certain instances, the age and the immune status of the host, the exposure history, and the virulent characteristics of the organism directly influence the likelihood of the development of meningitis.



Epidemiology


The use of conjugate vaccines against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae have significantly decreased the incidence of Hib as a meningeal pathogen and S. pneumoniae as a cause of invasive disease.5 Even as nonvaccine serotypes have emerged as “newly recognized” pathogens, S. pneumoniae remains an important adversary.6,7 The isolation of nonvaccine serotypes such as 19A, 22F, and 35B has increased since the introduction of the seven-valent vaccine. It is of great therapeutic concern that approximately 28% of these invasive isolates are resistant to penicillin and 11.8% are resistant to cefotaxime. Neisseria meningitidis is the second most common cause of sepsis and meningitis beyond the neonatal period. In a recent study of children with bacterial meningitis, one third of cases were by S. pneumoniae, while N. meningitidis was responsible for 28% of cases. Sixty-two percent of typed pneumococcal isolates were caused nonvaccine serotypes.8


In young infants in the first few months of life, Escherichia coli has become the main cause of sepsis and meningitis and is responsible for 22% of cases. Because of the use of intrapartum prophylaxis, Streptococcus agalactiae (group B Streptococcus [GBS]) is being observed less frequently.9 Other organisms such as Klebsiella pneumoniae, Enterobacter cloacae, Cronobacter spp. (formerly known as Enterobacter sakazakii),10 and Citrobacter koseri (formerly known as C. diversus) have been reported as causes of meningitis in young infants.


Listeria monocytogenes continues to be listed as a cause of sepsis and meningitis in the newborn. However, because the frequency of its occurrence in this age group is so low, most clinicians have never seen a case. A known association with specific dietary habits in the mother such as the consumption of unpasteurized soft cheeses, dairy products, and cold meat cuts has been recognized for years.


Children with asplenia, humoral immunodeficiencies, cochlear implants, human immunodeficiency virus (HIV), and cerebrospinal fluid (CSF) leakage resulting from trauma are at high risk of pneumococcal meningitis. Asplenic children and those with complement deficiencies are at risk for meningococcal meningitis. On rare occasions, Streptococcus pyogenes has been responsible for meningitis, with concurrent otitis media being a major risk factor.11 S. pyogenes was responsible for close to 2% of cases. Less frequent meningeal pathogens in young infants are Salmonella species and Capnocytophaga canimorsus, an organism associated with exposure of the mucous membranes to dog saliva.12


Rare causes of pediatric meningitis, such as Cryptococcus neoformans, Coccidioides spp., rickettsiae, ehrlichiosis, Mycobacterium tuberculosis, and Baylisascaris procyonis (raccoon roundworm) are well recognized for their high degree of morbidity and mortality. Meningoencephalitis also can result from tick bite–associated transmission of rickettsial pathogens such as Rickettsia rickettsii and ehrlichia. Infections by Staphylococcus aureus and coagulase-negative staphylococci are generally associated with neurosurgical surgery and trauma.





Diagnosis


When clinically feasible, the diagnosis of meningitis requires the examination of CSF. In most cases of bacterial meningitis, the diagnosis relies on the isolation of bacteria from a CSF specimen. Cell count and differential, along with protein and glucose determinations, Gram stain, and cultures, are essential tests to be performed. The use of blood cultures alone as an initial screening test is not appropriate. Approximately 80% of patients with bacterial meningitis will have a positive blood culture. This approach alone would result in a large number of cases being missed.


Lumbar puncture should be postponed in children with an ongoing coagulopathy, elevated ICP, or cardiorespiratory difficulty, and in patients with suspected mass-occupying lesions as demonstrated by focal neurologic signs. However, it is critical to remember that antimicrobial therapy and other supportive measures should not be delayed while waiting for results of CSF analysis. Routine end-of-treatment lumbar punctures are no longer recommended.14 Patients with multidrug resistant S. pneumoniae or Gram-negative bacilli meningitis should have a repeat lumbar puncture at 48 hours after initiation of therapy to document sterilization.


Although a computed tomography (CT) scan is not required in all children with suspected meningitis, it is indicated prior to lumbar puncture in patients with focal neurologic findings and signs of ICP. It is important to remember that even when CT scans are normal, herniation may still occur.15 Similar findings have been confirmed in adults with meningitis.16


CSF with pleocytosis (usually greater than 1000/μL) and a predominance of polymorphonuclear leukocytes is highly suggestive of bacterial meningitis. High protein and low glucose (usually < 1⁄2 serum value) concentrations also support the diagnosis. A predominance of lymphocytes and monocytes suggests a viral pathogen. A predominance of lymphocytes and monocytes also can be observed in patients with rickettsial and tuberculous meningitis. CSF eosinophils are frequently observed in patients with CSF shunt devices, but this also can be observed in persons with parasitic infections that result in meningoencephalitis, such as baylisascariasis and infections by Angiostrongylus species.


Clinicians must remember that a polymorphonuclear leukocyte predominance may be observed early in the course of enteroviral meningitis as well. Frequently, patients with this disease have normal CSF protein and glucose concentrations. However, hypoglycorrachia can be observed with certain viral pathogens such as enterovirus and mumps virus. On occasion, a small percentage of patients may have an initial “normal appearing” CSF analysis, especially with N. meningitidis.


Gram stains have been reported to demonstrate organisms in 50% to 75% of specimens. The impression of most clinicians is that it is not that high. The clinician is cautioned not to make significant changes in antimicrobial therapy based solely on a Gram stain result. CSF cultures remain the ultimate gold standard.


In most instances, prior oral antimicrobial therapy will not significantly alter CSF cell counts, differential, and chemistries in children with bacterial meningitis. In contrast, Gram stain and culture positivity are greatly reduced. Clinicians frequently are faced with the question of how to treat these patients and/or if there is a need for prophylaxis of household members if the infection happens to be caused by N. meningitidis.


Routine use of rapid bacterial antigen detection assays have been shown to be of limited clinical relevance because on most occasions therapy typically is not altered based on the result.17 However, in a multisite study from Asia and Africa, an immunochromatographic test for pneumococcal antigen was found to have high sensitivity and specificity. This assay may be useful in previously treated children with a negative CSF Gram stain and culture.18


Real-time fluorescent quantitative polymerase chain reaction (PCR) amplification of the bacterial 16S ribosomal ribonucleic acid (RNA) gene may become a useful clinical tool for the rapid diagnosis of bacterial meningitis. It would be particularly beneficial in patients who have taken antibiotics prior to undergoing a lumbar puncture. Compared with bacterial culture controls, sensitivity was 100% in one study; in another study it was 86% overall.19,20 This assay also may be useful for the prompt identification of S. pneumoniae and N. meningitidis as the etiologic agents.21 In a clinical setting, a real-time PCR for N. meningitidis was found to have a high sensitivity, specificity, and predictive values.22


Serum procalcitonin assays have been used to differentiate between bacterial and aseptic meningitis. In a small study, procalcitonin determination had 99% sensitivity and 83% specificity.23 A larger prospective study will be needed to assess the ultimate clinical role for this assay.


Susceptibility testing of most bacterial isolates is of clinical importance. In certain pathogens, however, it may not be required. Unless penicillin G is being considered for the treatment of meningococcal meningitis, susceptibility testing for this pathogen is not required. Similarly, penicillin or cephalosporin resistance is not currently recognized for S. pyogenes.



Treatment


An effective antimicrobial agent for the treatment of bacterial meningitis must be bactericidal and must achieve high concentrations in the CSF. In addition, initial empiric therapy should take into consideration antimicrobial resistance among the most likely meningeal pathogens. Once meningitis is suspected, antimicrobial therapy must be initiated promptly.


The Infectious Disease Society of America has published practice guidelines for the management of bacterial meningitis. All critical care clinicians should be familiar with their recommendations.24 Tables 65-1, 65-2, and 65-3 provide a listing of most frequent meningeal pathogens and recommended antimicrobial regimens along with dosage information.


Table 65–1 Initial Empiric Antimicrobial Therapy for Bacterial Meningitis Based on Presumptive Pathogen(s)















































Age and/or Predisposing Condition Pathogen Antimicrobial Therapy
<1 mo Escherichia coli, Streptococcus agalactiae, Klebsiella spp., Listeria monocytogenes Ampicillin + cefotaxime ± aminoglycoside
1–2 mo Streptococcus pneumoniae, Neisseria meningitidis, S. agalactiae, Haemophilus influenzae, E. coli Vancomycin + third-generation cephalosporin
2 mo–5 y S. pneumoniae, N. meningitidis, H. influenzae Vancomycin + third-generation cephalosporin
>5 y S. pneumoniae, N. meningitidis Vancomycin + third-generation cephalosporin
Humoral immunodeficiency, human immunodeficiency virus, asplenia S. pneumoniae, N. meningitidis, H. influenzae, Salmonella spp. Vancomycin + third-generation cephalosporin
Complement deficiencies N. meningitidis, S. pneumoniae Vancomycin + third-generation cephalosporin
Basilar skull fractures S. pneumoniae, N. meningitidis, Streptococcus pyogenes Vancomycin + third-generation cephalosporin
Cerebrospinal fluid, shunt related Coagulase-negative staphylococci, Staphylococcus aureus (methicillin-susceptible, methicillin-resistant), aerobic gram-negative bacilli (including Pseudomonas aeruginosa), Propionibacterium acnes Vancomycin + ceftazidime or vancomycin + cefepime or vancomycin + meropenem
After neurosurgery Coagulase-negative staphylococci, S. aureus (methicillin-susceptible, methicillin-resistant), aerobic gram-negative bacilli (including P. aeruginosa), P. acnes Vancomycin + ceftazidime or vancomycin + cefepime or vancomycin + meropenem
Cochlear implants S. pneumoniae Vancomycin + third-generation cephalosporin

Cefotaxime or ceftriaxone.


The choice of anti–gram-negative bacillary agent should be based on the institution’s susceptibility patterns.


Table 65–2 Antimicrobial Therapy for Specific Meningeal Pathogens










































Pathogen Antimicrobial Therapy
Streptococcus agalactiae Penicillin G ± gentamicin or ampicillin ± gentamicin
Hemophilus influenzae, β-lactamase–negative Ampicillin
H. influenzae, β-lactamase–positive Third-generation cephalosporin
Streptococcus pneumoniae, penicillin-susceptible Penicillin G or ampicillin
S. pneumoniae, penicillin-resistant, cephalosporin-susceptible Third-generation cephalosporin
S. pneumoniae, drug resistant (multiply resistant) Vancomycin + rifampin
Neisseria meningitidis Third-generation cephalosporin
N. meningitidis, penicillin-susceptible Penicillin G or ampicillin
Escherichia coli, other aerobic enteric gram-negative bacilli (not including Pseudomonas aeruginosa) Cefotaxime or ceftriaxone (if >1 mo of age) + aminoglycoside§
P. aeruginosa Meropenem + aminoglycoside or cefepime + aminoglycoside or ceftazidime + aminoglycoside§
Coagulase-negative staphylococci, methicillin-resistant Staphylococcus aureus Vancomycin ± rifampin
Methicillin-susceptible S. aureus Nafcillin

Cefotaxime or ceftriaxone.


Some clinicians prefer ampicillin because of less frequent dosing.


The choice of aminoglycoside will depend on the institution’s susceptibility patterns.


§ The choice of antipseudomonal regimen is influenced by the institution’s susceptibility patterns.



In the neonate with meningitis, empiric antimicrobial agents used initially should consist of ampicillin, an aminoglycoside, and cefotaxime. In infants older than 1 month, vancomycin and a third-generation cephalosporin (cefotaxime or ceftriaxone) is recommended. Alterations to these regimens may be influenced by Gram stain, culture, and drug susceptibility results. Additional empiric agents could be added according to epidemiologic exposures, underlying conditions, and the presence of resistant organisms in the community or hospital.


Once a specific pathogen has been identified and susceptibility data are available, antimicrobial therapy could be “narrowed” to specifically target the offending pathogen. It is the opinion of many clinicians that ampicillin or penicillin G plus gentamicin are the agents of choice for GBS meningitis in the young infant. Unless susceptibility is provided for penicillin, a third-generation cephalosporin is the agent of choice for patients with N. meningitidis. Because drug-resistant S. pneumoniae (DRSP) has become a problem in the United States, vancomycin plus cefotaxime or ceftriaxone, possibly with rifampin, may be indicated for the full course.


The duration of antimicrobial therapy will vary according to causative pathogen. Neonates with group B streptococcal meningitis require 14 to 21 days of antimicrobial therapy, and those with S. pneumoniae require 10 to 14 days; for neonates with N. meningitidis, most clinicians prescribe therapy for 7 days, and for those with H. influenzae, 7 to 10 days of therapy is required. Children with Gram-negative bacillary meningitis require a minimum of 3 weeks of antimicrobial therapy.




Adjunctive Therapy


Two agents, glycerol and dexamethasone, have been evaluated as candidates for possible adjuvant therapy in persons with meningitis. In various studies, orally administered glycerol had been shown to reduce neurologic sequelae in children with bacterial meningitis. It has been postulated that through an increase in serum osmolality, enhanced movement of water back into plasma would result in a reduction of CSF volume and an increase in cerebral blood flow.25,26 However, in a recently published multicenter trial, it was found that glycerol did not prevent hearing loss, which is a frequent neurologic sequelae.27


Corticosteroids such as dexamethasone (DXM) have a discernible effect on inflammatory markers in the CSF in persons with bacterial meningitis.28 Use of DXM in children remains a topic of controversy among clinicians. In adults with pneumococcal meningitis, the early administration of DXM (15 to 20 minutes before or with the first dose of an antibiotic) was associated with a reduction in mortality and unfavorable outcomes.29


In early studies in children with Hib meningitis, children treated with DXM had a lower incidence of moderate-to-severe hearing deficits when compared with placebo.30 However, one of the antimicrobial agents used in the study, cefuroxime, was later shown to be associated with increased neurologic sequelae. This single factor may have influenced the results for the placebo group. In a study by Peltola and Roine, DXM did not prevent neurologic sequelae in children with Hib meningitis; however, glycerol performed in a favorable manner.31 On the other hand, in a recently published multicenter study, neither agent was found to prevent hearing loss.27


In children with pneumococcal meningitis, DXM has not demonstrated the same magnitude of benefit as in adults. In one study, DXM use was associated with an increase in moderate or severe hearing loss and other neurologic deficits.32 As a consequence, some clinicians may elect not to administer DXM. However, many experts would agree to administer DXM if Hib meningitis was suspected (e.g., in an unimmunized child, in a child living in an endemic region with known Hib transmission, or in a child whose Gram stain shows pleomorphic gram-negative bacilli).33


In summary, studies of adjuvant corticosteroid therapy in children have not unequivocally demonstrated beneficial effects. Study design flaws and the fact that most studies were done in the era of Hib disease bring into question the applicability of these results to today’s practice. Meta-analysis and retrospective studies have demonstrated beneficial effects in persons with Hib and pneumococcal meningitis. However, these effects were demonstrated at a time when DRSP was not a serious problem. The data could support a beneficial effect in persons with Hib meningitis, but because this organism is an uncommon pathogen at this time, empiric therapy would not be warranted in most cases. In the era of DRSP, when an isolate may be resistant to the third-generation cephalosporin, it has been suggested that DXM may impair the diffusion of vancomycin through the BBB, delaying CSF sterilization. Thus the use of caution has merit. Some clinicians recommend the addition of rifampin under these circumstances. Further studies are needed in this patient population. Lastly, because maximal beneficial effect would be gained by administering DXM prior to antibiotic therapy, infants and children previously treated with antibiotics should not receive DXM.


There is no evidence that corticosteroids are beneficial in patients with viral or meningococcal or neonatal meningitis.34,35 In contrast, patients with tuberculous meningitis who are treated with steroids have an improved survival rate compared with those who are not treated with steroids. However, the severity of disability commonly observed in those with tuberculous meningitis is not altered.36





Subdural Empyema


Subdural collections complicating meningitis are common in young infants, and they occur in 40% of infants with proven pyogenic meningitis.45 However, these fluid collections are typically sterile and cause no long-term sequelae. Subdural empyemas (SDE) are serious CNS infections defined as purulent fluid collections outside the brain parenchyma but contained under the dura. They usually are encapsulated and often loculated. Historically, otorhinolaryngeal infections were an important predisposing factor to SDE in older children. However, a recent study demonstrated that only 10% of episodes were related to otorhinolaryngeal infections. The decrease in the incidence of SDE after sinus infections is presumed to be from increased antibiotic use for this disease process. Meningitis, head trauma, or neurosurgeries are now more common predisposing conditions for SDE.46


In adolescents and adults, subdural empyemas usually result from infection of the paranasal sinuses, middle ear, and face or, less frequently, from a penetrating skull fracture. In young infants, SDE is rare and is usually a complication of purulent meningitis wherein the infection extends through the arachnoid and into the subdural space.47 The sequelae of SDE may be more severe in young infants than in any other age group.48 The clinical symptoms can mimic mild meningitis, followed several days later by rapidly progressive drowsiness, neurologic deficits, and seizures. Prolonged fever (90%), seizures (70%), and focal neurologic signs (60%) are the most common clinical signs noted in the pediatric population.46


In children, SDE is commonly secondary to Hib or S. pneumoniae meningitis. SDE also occurs with Salmonella, N. meningitidis, E. coli, and neurotuberculosis. The most common pathogen in infants younger than 4 months of age is GBS.46


The diagnosis is often made with radiologic assistance and evaluation of the subdural fluid collection. Distinguishing an SDE from a sterile reactive subdural effusion (RSE). is often difficult.49 The differentiation of SDE from sterile RSE may not be possible if contrast enhancement of the inner membrane is not seen at CT. Magnetic resonance imaging (MRI) is superior to CT in the demonstration of both the extra-axial fluid and the enhancement of the inner membrane with a paramagnetic contrast medium. Still, there are no MRI characteristics that are specific for SDE compared with a nonpurulent RSE. Analysis of the subdural fluid often is required to establish the diagnosis of SDE. Serial cranial ultrasounds may be the modality of choice for the evaluation of response to medical management.48


The goal of treatment is evacuation of pus and eradication of the source of infection. Management choice should be related to the clinical condition. Medical treatment may be adequate if the empyema is small. A surgical approach is suggested in patients who are not responding well to medical treatment or in those who have large subdural pus accumulation with evidence of midline shift or elevated ICP. In infants whose anterior fontanelles are still wide open, transcutaneous subdural tapping may be another option but should be performed by an experienced clinician.


The keys to an optimal outcome in SDE are early, accurate diagnosis, timely intervention, and appropriate antibiotic therapy. The reported mortality rate of SDE is approximately 10%.46 Age, level of consciousness, timing and aggressiveness of treatment, and the rapidity of disease progression all influence outcome.



Meningoencephalitis


As more children are successfully immunized with vaccines to prevent bacterial meningitis, a greater proportion of children with CNS infections present to the PICU with viral meningoencephalitis. The initial signs and symptoms are often indistinguishable from bacterial meningitis, and a diagnosis of a viral rather than bacterial CNS infection does not decrease the chance of a patient becoming critically ill.


While the term meningitis implies that the meninges are primarily involved, encephalitis indicates brain parenchymal involvement. The presence or absence of normal brain function is important in distinguishing between aseptic meningitis and encephalitis. Patients with meningitis have fever, meningeal symptoms, and CSF pleocytosis but no evidence of bacterial or fungal infection and no associated neurologic dysfunction.50 Abnormal neurologic function, such as focal neurologic signs, cranial nerve involvement, motor deficits, sensory deficits, or speech difficulties, implies brain parenchymal involvement and encephalitis. Both meningitis and encephalitis may result in increased ICP, and patients may present with coma as a result of increased ICP or partial or complete brainstem herniation. Patients presenting with seizures may have meningitis or encephalitis. Making the distinction between meningitis and encephalitis is often difficult, and patients may present with both a parenchymal and meningeal process. Therefore, some clinicians prefer the term meningoencephalitis to recognize the inherent overlap between the two clinical entities.



Epidemiology


A survey of hospital discharge records from 1988 to 1997 showed approximately 19,000 hospitalizations per year (7.3 hospitalizations per 100,000 population), 230,000 hospital days, and 1400 deaths annually due to viral encephalitis in the United States.51 Children younger than 1 year had the highest risk for hospitalization as a result of encephalitis. Between the years 1989 to 1998, approximately 1100 deaths were attributed to encephalitis in children younger than 19 years in the United States. The highest rate of death occurred in children younger than 1 year (9.3 per 100,000 population).52 Nonviral causes of encephalitis are extremely rare.


Although the causative agent in many cases of encephalitis can be difficult to isolate, most cases are attributed to enteroviruses, herpesviruses, and arboviruses. Table 65-4 lists some of the common pathogens associated with meningoencephalitis. The enteroviruses and arboviruses in particular display seasonality in infection, being seen most frequently in the summer and autumn months. Herpesviruses, CMV, varicella-zoster virus (VZV), and Epstein-Barr virus (EBV) often show a predilection for the winter and spring. Herpes simplex virus (HSV), on the other hand, does not demonstrate any seasonality. With this epidemiology in mind, the evaluation of children with suspected viral meningoencephalitis is guided by many factors, including age, geographic location, season of the year, vaccination status, chronic conditions or immunosuppression, history of tick or mosquito exposure, and travel history.


Table 65–4 Causes of Meningoencephalitis and Available Laboratory Testing and Treatment









































































































































Virus Available Laboratory Testing Treatment
COMMON CAUSES    
Enterovirus   No specific therapy
Poliovirus (three serotypes) Cell culture; isolates sent to CDC via state laboratories  
Nonpoliovirus CSF PCR  
Echovirus (28 serotypes) Cell culture, CSF PCR  
Coxsackievirus A (23 serotypes) CSF PCR  
Coxsackievirus B (six serotypes) Cell culture, PCR  
Parechovirus (six serotypes) None  
Herpesvirus    
Herpes simplex virus-1, -2 CSF PCR Acyclovir, foscarnet (if resistant to acyclovir in immunocompromised patients)
Cytomegalovirus CSF PCR Ganciclovir, Foscarnet
Ebstein-Barr virus CSF PCR  
Varicella zoster CSF PCR Acyclovir
Human herpesvirus-6 CSF PCR  
Arbovirus Viral isolation, serology done by state and research laboratories, detection of virus-specific IgM in CSF + Ab in serum specimen; CSF PCR in reference laboratories  
Flavivirus    
St. Louis encephalitis    
West Nile virus    
Togavirus    
Eastern equine encephalitis virus    
Western equine encephalitis virus    
Bunyavirus    
California encephalitis virus    
La Crosse virus    
Jamestown virus    
Snowshoe virus    
LESS COMMON CAUSES    
Mumps Cell culture, mumps-specific IgM Ab, PCR  
Adenovirus CSF PCR, cell culture None
Respiratory syncytial virus Viral isolation from nasopharyngeal secretion in cell culture, PCR  
Influenza A and B Viral culture, PCR Oseltamivir, zanamivir, amantadine or rimantadine if susceptible
HIV HIV-1 nucleic acid detection by PCR Multiple drug regimens

< div class='tao-gold-member'>

Stay updated, free articles. Join our Telegram channel

Jul 7, 2016 | Posted by in CRITICAL CARE | Comments Off on Central Nervous System Infections Presenting to the Pediatric Intensive Care Unit

Full access? Get Clinical Tree

Get Clinical Tree app for offline access